

Best Practice Support Program in Diabetes Care: References

1. Total prevalence of diabetes in the United States, all ages, 2005. (Accessed September 24, 2007, at <http://www.cdc.gov/diabetes/pubs/estimates05.htm#prev>.)
2. Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. *N Engl J Med* 2006;355(23):2427–43.
3. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. *Diabetes Care* 2004;27:17–20.
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;281(21):2005–12.
5. American Diabetes Association. Standards of medical care in diabetes – 2007. *Diabetes Care* 2007;30:S4-S41.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997;20:1183–97.
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003;26:3160–7.
8. World Health Organization and International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization; 2006.
9. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. *Diabetes* 1976;25(12):1129–53.
10. Derosa G, Gaddi AV, Ciccarelli L, et al. Longterm effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. *The Journal of international medical research* 2005;33(3):284–94.
11. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Diabetes, obesity & metabolism* 2006;8(2):156–63.
12. Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and A1c: analysis of glucose profiles and A1c in the Diabetes Control and Complications Trial. *Diabetes Care* 2002;25:275–8.
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000;321:405–12.
14. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. *Diabetes Care* 2001;24:561–87.

15. American Diabetes Association. Self-monitoring of blood glucose. *Diabetes Care* 1994;17:81–6.
16. American Diabetes Association. Consensus statement on self-monitoring of blood glucose. *Diabetes Care* 1987;10:95–9.
17. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003;26(11):3080–6.
18. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–50.
19. Sigal RJ, Kenny GP, Boule NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. *Annals of internal medicine* 2007;147(6):357–69.
20. Boule NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA* 2001;286:1218–27.
21. US Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. *Ann Intern Med* 2004;140:569–72.
22. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. *Lancet* 2006;368(9548):1673–9.
23. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.
24. Chiasson J, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;359:2072–77.
25. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patient with impaired glucose tolerance of impaired fasting glucose: a randomised controlled trial. *Lancet* 2006;368(1096–1105).
26. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. *N Engl J Med* 2007;356(24):2457–71.
27. Singh S, Loke YK, Furberg CD. Long-term Risk of Cardiovascular Events With Rosiglitazone: A Metaanalysis. *JAMA* 2007;298(10):1189–95.
28. Solomon DH, Winkelmayr WC. Cardiovascular risk and the thiazolidinediones: déjà vu all over again? *Jama* 2007;298(10):1216–8.
29. Bolen S, Feldman L, Vassy J, et al. Systematic Review: Comparative Effectiveness and Safety of Oral Medications for type 2 diabetes Mellitus. *Ann Intern Med* 2007;147(6):386–99.
30. Bolen S, Wilson L, Vassy J, et al. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With type 2 diabetes: John Hopkins Evidence-based Practice Center; 2007.

31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352(9131):837–53.
32. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352(9131):854–65.
33. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366(9493):1279–89.
34. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiovascular Outcomes—An Interim Analysis. *N Engl J Med* 2007;357(1):28–38.
35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients with type 2 diabetes Mellitus: A Meta-analysis of Randomized Trials. *JAMA* 2007;298(10):1180–8.
36. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *Jama* 2007;298(2):194–206.
37. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. *Diabetes, obesity & metabolism* 2007;9(2):153–65.
38. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. *Diabetes, obesity & metabolism* 2007;9(2):194–205.
39. Rosiglitazone Maleate (marketed as Avandia, Avandamet, and Avandaryl) Information. 2007. (Accessed October 9, 2007, at <http://www.fda.gov/cder/drug/infopage/rosiglitazone/default.htm>.)
40. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane database of systematic reviews (Online)* 2006(1):CD002967.
41. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes care* 2005;28(5):1083–91.
42. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes care* 2005;28(5):1092–100.
43. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. *Diabetes care* 2004;27(11):2628–35.
44. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Annals of internal medicine* 2005;143(8):559–69.

45. Exenatide (marketed as Byetta) Information. 2007. (Accessed October 25, 2007, at <http://www.fda.gov/cder/drug/infopage/exenatide/>.)
46. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2006;29(8):1963–72.
47. Micromedex Healthcare Series, (electronic version). Thomson Micromedex, Greenwood Village, Colorado. (Accessed October 9, 2007, at <http://www.thomsonhc.com>.)
48. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA* 2004;291(3):335–42.
49. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. *Diabetes Care* 2004;27(7):1535–40.
50. Fanning EL, Selwyn BJ, Larne AC, DeFronzo RA. Improving efficacy of diabetes management using treatment algorithms in a mainly Hispanic population. *Diabetes Care* 2004;27(7):1638–46.
51. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. *Diabetes Care* 2005;28(2):337–442.
52. Korytkowski M. When oral agents fail: practical barriers to starting insulin. *Int J Obes Relat Metab Disord* 2002;26 Suppl 3:S18–24.
53. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. *Diabetes Care* 2005;28(11):2673–9.
54. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. *Ann Intern Med* 2006;145(2):125–34.
55. Pharmacists ASoH-S. AHFS Drug Information. Bethesda; 2002.
56. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. *Arch Intern Med* 2005;165(12):1337–44.
57. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. *Annals of internal medicine* 2003;138(12):952–9.
58. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. *Diabetes Care* 2003;26(8):2238–43.
59. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care* 2006;29(6):1269–74.

61. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia* 2006;49(3):442–51.
62. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *New England Journal of Medicine* 2007;357.
63. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. *Clin Ther* 2004;26(12):2034–44.
64. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005;28(2):260–5.
65. McMahon GT D, RG. Intention to treat—Initiating insulin in the 4-T study. *New England Journal of Medicine* 2007;357.
66. Pfizer Writes Off Exubera. 2007. (Accessed November 1, 2007, at http://www.forbes.com/markets/2007/10/18/pfizer-earningspharmaceuticals-markets-equities-cx_cg_1018markets17.html.)
67. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. *Ann Intern Med* 2001;134(3):203–7.
68. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2005;143(8):549–58.
69. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. *Arch Intern Med* 1996;156(3):259–64.
70. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. *Diabetes Care* 1992;15(8):953–9.
71. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* 1999;130(5):389–96.
72. Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. *Diabetes Care* 2004;27(7):1577–83.
73. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. *Diabetes care* 2002;25(4):724–30.
74. Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. *J Am Geriatr Soc* 2003;51(5 Suppl Guidelines):S265–80.
75. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003;289(19):2560–72.

76. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet* 2000;355(9200):253–9.
77. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359(9311):1004–10.
78. Matcher DB, McCrory DC, Orlando LA, et al. Draft Comparative Effectiveness Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Antiotensin II Receptor Antagonists (ARBs) for Treating Hypertension. Durham, NC: Duke Evidence-Based Practice Center; 2006.
79. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Jama* 2002;288(23):2981–97.
80. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. *Ann Intern Med* 2001;135:825–34.
81. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495–504.
82. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 2004;292:1307–16.
83. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003;361:2005–16.
84. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997;20:614–20.
85. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;339:1349–57.
86. Law MR, et al. Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and metaanalysis. *BMJ* 2003;326:1423–XX.
87. American Diabetes Association. Aspirin therapy in diabetes (position statement). *Diabetes Care* 2004;27(S1):S72-S3.
88. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. *Am J Cardiol* 2002;90:625-8.
89. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian Primary Care Setting (results of the diabetes in Canada evaluation study). *Diabetes Research and Clinical Practice* 2005; 70: 90–97

90. Ko GT, Tsang PC, Henden PS. et al. Rosiglitazone versus Bedtime Insulin in the Treatment of Patients with Conventional Oral Antidiabetic Drug Failure: A 1 year randomized Controlled Trial. *Advances in Therapy* 2006 Sep/Oct; 23(5): 799–808
91. Dailey G. New Strategies for Basal Insulin Treatment in type 2 diabetes mellitus. *Clinical Therapeutics* 2004; 26 (6): 889–98
92. Gerstein HC, Yale JF, Harris et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. *The Canadian Insight—Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment. Diabetic Medicine* 2006; 23: 736–42.
93. Public Health Agency of Canada. National Diabetes Fact Sheet Canada, 2007.
94. Canadian Optimal Medication Prescribing and Utilization Service. Rapid-acting insulin analogues for diabetes mellitus: systematic review and metaanalyses of clinical outcomes. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
95. Canadian Diabetes Association. Clinical Practice Guidelines Expert Committee. Dyslipidemia in Adults with Diabetes. *Canadian Journal of Diabetes*. 2006; 30(3): 230-240